VRCA Earnings — Verrica Pharmaceuticals Inc. Common Stock Post-ER Performance | BigEarnings
VRCA — Verrica Pharmaceuticals Inc. Common Stock
XNAS
Price$6.17
Market Cap$104.1M
P/E—
52W Range$3.28 – $9.82
Next Earnings2026-08-11
About Verrica Pharmaceuticals Inc. Common Stock
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.